Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSepúlveda, María-
dc.contributor.authorArmangué, Thaís-
dc.contributor.authorSola Valls, Nuria-
dc.contributor.authorArrambide, Georgina-
dc.contributor.authorMeca Lallana, José E.-
dc.contributor.authorOreja-Guevara, Celia-
dc.contributor.authorMendibe, Mar-
dc.contributor.authorAlvarez de Arcaya, Amaya-
dc.contributor.authorAladro, Yolanda-
dc.contributor.authorCasanova, Bonaventura-
dc.contributor.authorOlascoaga, Javier-
dc.contributor.authorJiménez Huete, Adolfo-
dc.contributor.authorFernandez Fournier, Mireya-
dc.contributor.authorRamió Torrentà, Lluís-
dc.contributor.authorCobo Calvo, Álvaro-
dc.contributor.authorViñals, Montserrat-
dc.contributor.authorAndrés, Clara de-
dc.contributor.authorMeca Lallana, Virginia-
dc.contributor.authorCervelló, Angeles-
dc.contributor.authorCalles, Carmen-
dc.contributor.authorBarón Rubio, Manuel-
dc.contributor.authorRamo Tello, Cristina-
dc.contributor.authorCaminero, Ana-
dc.contributor.authorMunteis, Elvira-
dc.contributor.authorAntigüedad, Alfredo R.-
dc.contributor.authorBlanco, Yolanda-
dc.contributor.authorVilloslada, Pablo-
dc.contributor.authorMontalbán Gairín, Xavier-
dc.contributor.authorGraus Ribas, Francesc-
dc.contributor.authorSaiz Hinajeros, Albert-
dc.contributor.authorSpanish NMO Study Group-
dc.description.abstractObjective: To (1) determine the value of the recently proposed criteria of neuromyelitis optica (NMO) spectrum disorder (NMOSD) that unify patients with NMO and those with limited forms (NMO/LF) with aquaporin-4 immunoglobulin G (AQP4-IgG) antibodies; and (2) investigate the clinical significance of the serologic status in patients with NMO. Methods: This was a retrospective, multicenter study of 181 patients fulfilling the 2006 NMO criteria (n = 127) or NMO/LF criteria with AQP4-IgG (n = 54). AQP4-IgG and myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) antibodies were tested using cell-based assays. Results: Patients were mainly white (86%) and female (ratio 6.5:1) with median age at onset 39 years (range 10-77). Compared to patients with NMO and AQP4-IgG (n = 94), those with NMO/LF presentedmore often with longitudinally extensive transverse myelitis (LETM) (p<0.001), and had lower relapse rates (p = 0.015), but similar disability outcomes. Nonwhite ethnicity and optic neuritis presentation doubled the risk for developing NMO compared with white race (p = 0.008) or LETM presentation (p = 0.008). Nonwhite race (hazard ratio [HR] 4.3, 95% confidence interval [CI] 1.4-13.6) and older age at onset were associated with worse outcome (for every 10-year increase, HR 1.7, 95% CI 1.3-2.2). Patients with NMO and MOG-IgG (n = 9) had lower female: male ratio (0.8:1) and better disability outcome than AQP4-IgG-seropositive or double-seronegative patients (p<0.001). Conclusions: In patients with AQP4-IgG, the similar outcomes regardless of the clinical phenotype support the unified term NMOSD; nonwhite ethnicity and older age at onset are associated with worse outcome. Double-seronegative and AQP4-IgG-seropositive NMO have a similar clinical outcome. The better prognosis of patients with MOG-IgG and NMO suggests that phenotypic and serologic classification is useful.-
dc.format.extent9 p.-
dc.publisherLippincott Williams & Wilkins-
dc.relation.isformatofReproducció del document publicat a:
dc.relation.ispartofNeurology-Neuroimmunology & Neuroinflammation, 2016, vol. 3, num. 3-
dc.rightscc by-nc-nd (c) American Academy of Neurology, 2016-
dc.subject.classificationMalalties del nervi òptic-
dc.subject.classificationMalalties del sistema nerviós central-
dc.subject.otherOptic nerve diseases-
dc.subject.otherCentral nervous system diseases-
dc.titleNeuromyelitis optica spectrum disorders. Comparison according to the phenotype and serostatus-
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
SepulvedaM.pdf313.08 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons